Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory sign...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Vascular Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/648167 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550796510625792 |
|---|---|
| author | Koichi Yoshimura Hiroki Aoki |
| author_facet | Koichi Yoshimura Hiroki Aoki |
| author_sort | Koichi Yoshimura |
| collection | DOAJ |
| description | Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory signaling pathways through proinflammatory mediators shifts the balance of extracellular matrix (ECM) metabolism toward tissue degradation. This idea is supported by experimental evidence in animal models that pharmacologic intervention at each pathological step can prevent AAA development. Previously, we identified c-Jun N-terminal kinase (JNK), a pro-inflammatory signaling molecule, as a therapeutic target for AAA. Abnormal activation of JNK in AAA tissue regulates multiple pathological processes in a coordinated manner. Pharmacologic inhibition of JNK tips the ECM balance back towards repair rather than degradation. Interventions targeting signaling molecules such as JNK in order to manipulate multiple pathological processes may be an ideal therapeutic strategy for AAA. Furthermore, the development of biomarkers as well as appropriate drug delivery systems is essential to produce clinically practical pharmacotherapy for AAA. |
| format | Article |
| id | doaj-art-9880590f7bc746eb90c5d240d3c0cd2b |
| institution | Kabale University |
| issn | 2090-2824 2090-2832 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Vascular Medicine |
| spelling | doaj-art-9880590f7bc746eb90c5d240d3c0cd2b2025-02-03T06:05:47ZengWileyInternational Journal of Vascular Medicine2090-28242090-28322012-01-01201210.1155/2012/648167648167Recent Advances in Pharmacotherapy Development for Abdominal Aortic AneurysmKoichi Yoshimura0Hiroki Aoki1Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755-8505, JapanCardiovascular Research Institute, Kurume University, Kurume, Fukuoka 830-0011, JapanAbdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory signaling pathways through proinflammatory mediators shifts the balance of extracellular matrix (ECM) metabolism toward tissue degradation. This idea is supported by experimental evidence in animal models that pharmacologic intervention at each pathological step can prevent AAA development. Previously, we identified c-Jun N-terminal kinase (JNK), a pro-inflammatory signaling molecule, as a therapeutic target for AAA. Abnormal activation of JNK in AAA tissue regulates multiple pathological processes in a coordinated manner. Pharmacologic inhibition of JNK tips the ECM balance back towards repair rather than degradation. Interventions targeting signaling molecules such as JNK in order to manipulate multiple pathological processes may be an ideal therapeutic strategy for AAA. Furthermore, the development of biomarkers as well as appropriate drug delivery systems is essential to produce clinically practical pharmacotherapy for AAA.http://dx.doi.org/10.1155/2012/648167 |
| spellingShingle | Koichi Yoshimura Hiroki Aoki Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm International Journal of Vascular Medicine |
| title | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
| title_full | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
| title_fullStr | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
| title_full_unstemmed | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
| title_short | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
| title_sort | recent advances in pharmacotherapy development for abdominal aortic aneurysm |
| url | http://dx.doi.org/10.1155/2012/648167 |
| work_keys_str_mv | AT koichiyoshimura recentadvancesinpharmacotherapydevelopmentforabdominalaorticaneurysm AT hirokiaoki recentadvancesinpharmacotherapydevelopmentforabdominalaorticaneurysm |